Essential hypertension: leukocyte rheology and polymorphonuclear cytosolic Ca2+ content at baseline and after activation.
In 24 hypertensives we evaluated, at baseline, the leukocyte filtration parameters (using the St. George's Filtrometer), polymorphonuclear (PMN) membrane fluidity (with the fluorescent probe 1-[4-(trimethylamino)phenyl]-6-phenyl-1,3,5-hexatriene [TMA-DPH]) and PMN cytosolic Ca2+ content (with the fluorescent probe Fura 2-AM). In a subgroup of hypertensives (n = 17) the PMN filtration parameters, PMN membrane fluidity and cytosolic Ca2+ content were evaluated after in vitro chemotactic activation (prolonged for 5 and 15 min) with two stimulating agents (4-phorbol 12-myristate 13-acetate [PMA] and N-formyl-methionyl-leucyl-phenylalanine [fMLP]). It was evident, from the baseline data, that there was a significant difference in the mononuclear (MN) initial relative flow rate (IRFR), clogging rate (CR) and clogging particles (CP), and in PMN cytosolic Ca2+ content. There were, however, no differences in the filtration parameters of unfractionated leukocytes and PMNs or in PMN membrane fluidity. After activation, in normals and in hypertensives, a significant variation in PMN filtration parameters was evident. In normals no variation was present in PMN membrane fluidity or cytosolic Ca2+ content after activation. In hypertensives, however, we found an increase solely in PMN cytosolic Ca2+ content after fMLP activation. After PMN activation (at 15 min) one parameter (IRFR) of PMN filtration distinguished normal subjects from hypertensives. No difference between the two groups was found in PMN membrane fluidity or PMN cytosolic Ca2+ content after PMN activation.
Caimi
G
G
Istituto di Clinica Medica e Malattie Cardiovascolari Università di Palermo, Italy.
Lo Presti
R
R
Canino
B
B
Montana
M
M
Ferrara
L
L
Oddo
G
G
Ventimiglia
G
G
Cerasola
G
G
D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood*; D002630:Chemotactic Factors / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D005260:Female; D018056:Hemorheology; D006801:Humans; D006973:Hypertension / Q000097:blood*; D007962:Leukocytes / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008560:Membrane Fluidity / Q000187:drug effects; D008875:Middle Aged; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D018375:Neutrophil Activation / Q000187:drug effects; D009504:Neutrophils / Q000737:chemistry* / Q000187:drug effects; D012907:Smoking / Q000097:blood; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014462:Ultrafiltration